Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $32.00.

Several equities analysts recently weighed in on the stock. Stephens set a $32.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, May 7th. HC Wainwright lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Wall Street Zen cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Finally, Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in CPRX. State Street Corp boosted its position in Catalyst Pharmaceuticals by 7.8% in the 4th quarter. State Street Corp now owns 6,907,622 shares of the biopharmaceutical company’s stock valued at $161,224,000 after buying an additional 502,235 shares during the last quarter. Deerfield Management Company L.P. increased its position in shares of Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after acquiring an additional 2,095,291 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Catalyst Pharmaceuticals by 14.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,429,615 shares of the biopharmaceutical company’s stock worth $84,908,000 after acquiring an additional 433,318 shares in the last quarter. Fundsmith LLP lifted its stake in shares of Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after acquiring an additional 654,721 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock valued at $76,035,000 after purchasing an additional 333,100 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.2%

CPRX opened at $31.34 on Wednesday. Catalyst Pharmaceuticals has a 52-week low of $19.05 and a 52-week high of $32.56. The company has a 50 day moving average of $28.74 and a two-hundred day moving average of $25.47. The company has a market cap of $3.84 billion, a P/E ratio of 18.01, a P/E/G ratio of 0.95 and a beta of 0.74.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).